留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

器官移植术后结核病临床诊疗技术规范(2019版)

中华医学会器官移植学分会

中华医学会器官移植学分会. 器官移植术后结核病临床诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(4): 359-363. doi: 10.3969/j.issn.1674-7445.2019.04.003
引用本文: 中华医学会器官移植学分会. 器官移植术后结核病临床诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(4): 359-363. doi: 10.3969/j.issn.1674-7445.2019.04.003
Branch of Organ Transplantation of Chinese Medical Association. Technical specification for clinical diagnosis and treatment of tuberculosis after organ transplantation (2019 edition)[J]. ORGAN TRANSPLANTATION, 2019, 10(4): 359-363. doi: 10.3969/j.issn.1674-7445.2019.04.003
Citation: Branch of Organ Transplantation of Chinese Medical Association. Technical specification for clinical diagnosis and treatment of tuberculosis after organ transplantation (2019 edition)[J]. ORGAN TRANSPLANTATION, 2019, 10(4): 359-363. doi: 10.3969/j.issn.1674-7445.2019.04.003

器官移植术后结核病临床诊疗技术规范(2019版)

doi: 10.3969/j.issn.1674-7445.2019.04.003
基金项目: 

国家自然科学基金 81570680

国家自然科学基金 81571555

详细信息
    通讯作者:

    石炳毅,Email:shibingyi666@126.com

  • 中图分类号: R617, R52

Technical specification for clinical diagnosis and treatment of tuberculosis after organ transplantation (2019 edition)

  • 摘要: 结核病是实体器官移植后一种较为少见但后果严重的感染性疾病。随着器官移植受者以及结核病患病人数的增加,需要建立规范的诊疗程序和治疗指导原则,以便合理制定化学治疗和免疫抑制方案。为了进一步规范实体器官移植术后结核病的临床诊疗,中华医学会器官移植学分会组织器官移植学专家和结核病学专家,从实体器官移植术后结核病的流行病学特点、诊断、预防和治疗等方面,在《中国器官移植术后结核病临床诊疗指南(2016版)》的基础上制定本规范。

     

  • 表  1  部分抗结核药物对免疫抑制剂的影响作用

    Table  1.   Effect of some antituberculosis drugs on immunosuppressive agents

    免疫抑制剂 异烟肼 利福平或利福喷丁 吡嗪酰胺 乙胺丁醇 链霉素 莫西沙星或左氧氟沙星
    糖皮质激素 提高糖皮质激素水平,增加其不良反应(肝代谢抑制) 降低糖皮质激素水平及效果(肝代谢诱导) 无影响 无影响 无影响 增加肌腱相关的不良反应
    环孢素 无影响 降低环孢素血药浓度及疗效(肝代谢诱导) 无影响 无影响 增加肾毒性的风险(增加毒性) 增加环孢素血药浓度(仅左氧氟沙星)
    他克莫司 无影响 降低他克莫司血药浓度及疗效(肝代谢诱导) 无影响 无影响 增加肾毒性的风险(增加毒性) 无影响
    西罗莫司 无影响 降低西罗莫司血药浓度及疗效(肝代谢诱导) 无影响 无影响 无影响 无影响
    吗替麦考酚酯 无影响 使用替代或监测吗替麦考酚酯水平,与之联合使用可降低吗替麦考酚酯血药浓度及疗效(肠肝循环障碍) 无影响 无影响 无影响 降低吗替麦考酚酯的血药浓度
    下载: 导出CSV
  • [1] GRADE working group[EB/OL]. [2018-12-20]. http://www.gradeworkinggroup.org/index.htm.
    [2] SUBRAMANIAN A, DORMAN S, AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis in solid organ transplant recipients[J]. Am J Transplant, 2009, 9 (Suppl 4): S57-S62. DOI: 10.1111/j.1600-6143.2009.02894.x.
    [3] EPSTEIN DJ, SUBRAMANIAN AK. Prevention and management of tuberculosis in solid organ transplant recipients[J]. Infect Dis Clin North Am, 2018, 32(3):703-718. DOI: 10.1016/j.idc.2018.05.002.
    [4] MAJEED A, BEATTY N, IFTIKHAR A, et al. A 20-year experience with nocardiosis in solid organ transplant (SOT) recipients in the Southwestern United States: a single-center study[J]. Transpl Infect Dis, 2018, 20(4):e12904. DOI: 10.1111/tid.12904.
    [5] HORNE DJ, NARITA M, SPITTERS CL, et al. Challenging issues in tuberculosis in solid organ transplantation[J]. Clin Infect Dis, 2013, 57(10):1473-1482. DOI: 10.1093/cid/cit488.
    [6] BAKER RJ, MARK PB, PATEL RK, et al. Renal association clinical practice guideline in post-operative care in the kidney transplant recipient[J]. BMC Nephrol, 2017, 18(1):174. DOI: 10.1186/s12882-017-0553-2.
    [7] TORRE-CISNEROS J, DOBLAS A, AGUADO JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish network of infection in transplantation) cohort[J]. Clin Infect Dis, 2009, 48(12):1657-1665. DOI: 10.1086/599035.
    [8] REIS-SANTOS B, GOMES T, HORTA BL, et al. Tuberculosis prevalence in renal transplant recipients: systematic review and Meta-analysis[J]. J Bras Nefrol, 2013, 35(3):206-213. DOI: 10.5935/0101-2800.20130033.
    [9] YEHIA BR, BLUMBERG EA. Mycobacterium tuberculosis infection in liver transplantation[J]. Liver Transpl, 2010, 16(10):1129-1135. DOI: 10.1002/lt.22133.
    [10] SUBRAMANIAN AK, MORRIS MI, AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis infections in solid organ transplantation[J]. Am J Transplant, 2013, 13 (Suppl 4):68-76. DOI: 10.1111/ajt.12100.
    [11] BUMBACEA D, AREND SM, EYUBOGLU F, et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement[J]. Eur Respir J, 2012, 40(4):990-1013. doi: 10.1183/09031936.00000712
    [12] SUN HY. Treating tuberculosis in solid organ transplant recipients[J]. Curr Opin Infect Dis, 2014, 27(6):501-505. DOI: 10.1097/QCO.0000000000000102.
    [13] BOSCH A, VALOUR F, DUMITRESCU O, et al.A practical approach to tuberculosis diagnosis and treatment in liver transplant recipients in a low-prevalence area[J]. Med Mal Infect, 2019, 49(4): 231-240. DOI: 10.1016/j.medmal.2018.11.013.
    [14] LOPEZ DE CASTILLA D, SCHLUGER NW. Tuberculosis following solid organ transplantation[J]. Transpl Infect Dis, 2010, 12(2):106-112. DOI: 10.1111/j.1399-3062.2009.00475.x.
    [15] RAFIEI N, WILLIAMS J, MULLEY WR, et al. Mycobacterium tuberculosis: active disease and latent infection in a renal transplant cohort[J]. Nephrology (Carlton), 2019, 24(5):569-574. DOI: 10.1111/nep.13386.
    [16] KANWAL S, AKHTAR AM, AHMED A. Factors associated with mortality to drug-resistant tuberculosis and their programmatic management in treatment centres of Punjab, Pakistan[J]. J Pak Med Assoc, 2017, 67(6):858-862.
    [17] ABAD CLR, RAZONABLE RR. Donor derived mycobacterium tuberculosis infection after solid-organ transplantation: a comprehensive review[J]. Transpl Infect Dis, 2018, 20(5): e12971. DOI: 10.1111/tid.12971.
    [18] WU X, CHEN P, WEI W, et al. Diagnostic value of the interferon-γ release assay for tuberculosis infection in patients with Behçet's disease[J]. BMC Infect Dis, 2019, 19(1):323. DOI: 10.1186/s12879-019-3954-y.
    [19] HEYMANN WR. The hydroxychloroquine-interferon gamma release assay question: TB or not TB?[J]. J Am Acad Dermatol, 2019, 80(4):902-903. DOI: 10.1016/j.jaad.2019.01.070.
    [20] BENNET R, NEJAT S, ERIKSSON M. Effective tuberculosis contact investigation using interferon-gamma release assays[J]. Pediatr Infect Dis J, 2019, 38(4):e76-e78. DOI: 10.1097/INF.0000000000002272.
    [21] KUNIHIRO Y, TANAKA N, KAWANO R, et al. Differential diagnosis of pulmonary infections in immunocompromised patients using high-resolution computed tomography[J]. Eur Radiol, 2019. DOI: 10.1007/s00330-019-06235-3[Epub ahead of print].
    [22] GIACOMELLI IL, SCHUHMACHER NETO R, NIN CS, et al. High-resolution computed tomography findings of pulmonary tuberculosis in lung transplant recipients[J]. J Bras Pneumol, 2017, 43(4):270-273. DOI: 10.1590/S1806-37562016000000306.
    [23] SCHUHMACHER NETO R, GIACOMELLI IL, SCHULLER NIN C, et al. High-resolution CT findings of pulmonary tuberculosis in liver transplant patients[J]. Clin Radiol, 2017, 72(10):899.e9-899.e14. DOI: 10.1016/j.crad.2017.05.006.
    [24] GIACOMELLI IL, SCHUHMACHER NETO R, MARCHIORI E, et al. Chest X-ray and chest CT findings in patients diagnosed with pulmonary tuberculosis following solid organ transplantation: a systematic review[J]. J Bras Pneumol, 2018, 44(2):161-166. DOI: 10.1590/s1806-37562017000000459.
  • 加载中
表(1)
计量
  • 文章访问数:  239
  • HTML全文浏览量:  157
  • PDF下载量:  80
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-04-08
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2019-07-15

目录

    /

    返回文章
    返回